Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.

Autor:	Tamiya, Motohiro, Fujikawa, Kei, Suzuki, Hidekazu, Yokoyama, Toshihide, Uenami, Takeshi, Tamiya, Akihiro, Sato, Yuki, Saito, Go, Uchida, Junji, Morita, Mitsunori, Hirashima, Tomonori, Fukuda, Yasushi, Kanazu, Masaki, Hosoya, Kazutaka, Suzuki, Takuji, Ueno, Kiyonobu, Fujimoto, Daichi, Kumagai, Toru, Teramukai, Satoshi
Předmět:	LUNG cancer GENETIC mutation CONFIDENCE intervals REGRESSION analysis PROTEIN-tyrosine kinase inhibitors AFATINIB DESCRIPTIVE statistics TUMOR markers ODDS ratio DATA analysis software DRUG resistance in cancer cells
Zdroj:	Investigational New Drugs; Apr2022, Vol. 40 Issue 2, p361-369, 9p
Abstrakt:	Background and objective. Osimertinib as first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor (EGFR) mutations remains controversial. Sequential EGFR-tyrosine kinase inhibitor (TKI) might be superior to the first line osimertinib in patients at risk of developing acquired T790M mutations. Methods. We enrolled consecutive patients with EGFR-mutated (deletion 19 or L858R) advanced NSCLC treated with first-line drugs and evaluated predictive markers using classification and regression tree (CART) for the detection of T790M mutations based on patient backgrounds prior to initial treatment. Results. Patients without acquired T790M mutations had worse outcomes than those with T790M mutations (median OS: 798 days vs. not reached; HR: 2.70; P < 0.001). CART identified three distinct groups based on variables associated with acquired T790M mutations (age, CYF, WBC, liver metastasis, and LDH; AUROC: 0.77). Based on certain variables, CART identified three distinct groups in deletion 19 (albumin, LDH, bone metastasis, pleural effusion, and WBC; AUROC: 0.81) and two distinct groups in L858R (age, CEA, and ALP; AUROC: 0.80). The T790M detection frequencies after TKI resistance of afatinib and first-generation EGFR-TKIs were similar (35.3% vs. 37.4%, P = 0.933). Afatinib demonstrated longer PFS (398 vs. 279 days; HR: 0.67; P = 0.004) and OS (1053 vs. 956 days; HR: 0.68; P = 0.051) than first-generation EGFR-TKIs. Conclusion. Identification of patients at risk of acquiring T790M mutations after EGFR-TKI failure may aid in choice of first-line EGFR-TKI. Furthermore, afatinib may be the more effective 1st-line EGFR-TKI treatment for patients at risk of developing T790M as initial EGFR-TKI resistance. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink